

Review of infective dose, routes of transmission, and outcome of COVID-19 caused by the SARS-COV2 virus: comparison with other respiratory viruses

Running title: COVID-19 infective dose review

Sedighe Karimzadeh^{1*}, *Raj Bhopal*^{2*}, *Nguyen Tien Huy*³

Affiliation

¹School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

²Usher Institute, University of Edinburgh, Edinburgh EH3 9AG, UK

³School of Tropical Medicine and Global Health, Nagasaki University, Japan

*Correspondence to Sedighe Karimzadeh, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran. (E-Mail: sediqekarimzadeh@gmail.com) or

Raj Bhopal, Usher Institute, University of Edinburgh, Edinburgh EH3 9AG, UK

(E-Mail: Raj.Bhopal@ed.ac.uk)

Authors email:

SK: sediqekarimzadeh@gmail.com

RB: Raj.Bhopal@ed.ac.uk

NTH: tienhuy@nagasaki-u.ac.jp

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. Prevention and control strategies require an improved understanding of SARS-CoV-2 dynamics. We did a rapid review of the literature on SARS-CoV-2 viral dynamics with a focus on infective dose. We sought comparisons of SARS-CoV-2 with other respiratory viruses including SARS-CoV-1 and MERS-CoV. We examined laboratory animal, and human studies. The literature on infective dose, transmission, and routes of exposure was limited specially in humans, and varying endpoints were used for measurement of infection. We propose the minimum infective dose of COVID-19 in humans, is higher than 100 particles, possibly slightly lower than the 700 particles estimated for H1N1 influenza. Despite variability in animal studies, there was some evidence that increased dose at exposure correlated with higher viral load clinically, and severer symptoms. Higher viral load measures did not reflect COVID-19 severity. Aerosol transmission seemed to raise the risk of more severe respiratory complications in animals. An accurate quantitative estimate of the infective dose of SARS-CoV-2 in humans is not currently feasible and needs further research. Further work is also required on the relationship between routes of transmission, infective dose, co-infection, and outcomes.

Keywords: infective dose, SARS-CoV-2, COVID-19, respiratory viruses, viral load, viral dynamics

Abbreviation:

BALB/c:	begeg albino laboratory-bred
C57BL/6:	c57 black strain 6
COVID-19:	coronavirus disease 2019
CPE:	cytopathogenic effect
hACE2:	human angiotensin converting enzyme 2
ID ₅₀ :	median infectious dose
MERS:	middle east respiratory syndrome
PFU:	plaque forming unit
RSV:	respiratory syncytial virus
SARS:	severe acute respiratory syndrome
TCID ₅₀ :	median tissue culture infective dose
tgMice:	transgenic mice

1. Introduction

COVID-19 is a severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) which is now pandemic. Several fundamental virologic concepts relating to COVID-19 remain poorly understood such as the initiating event and infective dose i.e. number of particles to cause a detectable infection. It is unclear whether the number of particles on exposure is correlated with the severity and outcome of disease. Understanding of these concepts requires experimental studies to complement epidemiologic data that can only provide limited insights into these matters. Improved understanding of viral concepts of COVID-19 can promote more effective outbreak control strategies. We did a rapid review of the evidence for the infectious dose, viral load, co-infection, route of transmission, and correlation with the outcome of SARS-CoV-2 infection. To help interpret the limited data available we compared viral dynamics of SARS-CoV-2 with other respiratory pathogens such as influenza virus, SARS-CoV-1 and MERS-CoV viruses.

2. Methods

We identified relevant data for this review by searching databases including PubMed and Google Scholar, using the terms “Infective dose”, “Respiratory viruses”, “SARS-CoV”, “MERS-CoV”, “Aerosol”, “COVID-19”, “viral load”, “Coronavirus”, “Influenza virus”. The latest literature search was performed on Sep 1, 2020 with no restriction on date of publication and study design. We included articles published in English with full-text version available. We did not limit our search to peer-reviewed journals.

3. Result

We included 79 experimental and human studies exploring the infective dose, viral load, route of administration, exposure, and outcome in respiratory viruses. We extracted data for respiratory viruses including coronaviruses (Seasonal CoV, SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza virus, rhinovirus, coxsackievirus, adenovirus and respiratory syncytial virus (RSV).

3.1. Infective dose

For comprehension of viral pathogenicity, determining the number of particles that trigger infection is crucial. A low infectious dose could mean the organism is highly transmissible person-to-person and via touching contaminated surfaces (1). The main methods for defining the infective viral dose is through studies utilizing dilution of virus studies for cytopathogenic effect (CPE) in 50% of inoculated culture cells (known as tissue culture infectious dose, or TCID₅₀), or by counting plaque-forming units; each plaque in a layer of host cells indicating colonization by a single virus particle (PFU) (2). TCID₅₀ is the viral dose that induces either pathological changes or cell death in 50% of inoculated tissue cultures. The viral plaque assay is a quantitative measure of the number of particles that form a plaque, estimating viral concentration in plaque-forming units (3). A virus titer of 0.7 PFU can be estimated as theoretically equivalent to 1 TCID₅₀, so given that most studies reported the latter we converted the results for those reporting PFU (3). For determining the infectious dose (ID₅₀) in humans the viral administration should, ideally, be in controlled experiments. Since patient safety concerns would usually make this unethical, animal-based experimental studies are mostly used for simulating infection in humans (4). We have summarized in tables 1 and 2 the infectious dose reported for some major human respiratory viruses identified by either experimental infection in human volunteers or laboratory animals.

3.2. Human studies on infective dose of COVID-19 and other relevant viruses

Irrespective of the route of inoculation, some respiratory viruses such as rhinoviruses and adenoviruses mostly cause asymptomatic or mild respiratory symptoms in immunocompetent hosts. Although the minimum infective dose causing COVID-19 in humans is unknown it is assumed to be low since the virus transmits rapidly. The route of inoculation affects the response to viruses (4). Infective dose assessment in human studies requires intranasal administration of the virus via drops or aerosols. Infection with drops informs us about upper respiratory tract infection, while aerosols can inform about lower respiratory tract infection (4).

We found no experimental studies of this kind in humans but one observational study. Isolation of SARS-CoV-2 from oropharyngeal and nasopharyngeal sample of one patient in the USA and inoculation in Vero cells shows that SARS-CoV-2 can replicate rapidly and achieve 10⁵ TCID₅₀/mL within 24-hour post-infection (5) (Study not tabulated). Although virus titer peaked at >10⁶ TCID₅₀/mL after 48 hour post-inoculation, major CPE (cytopathogenic effect) was

observed after 60 hours post-inoculation (5). This infective dose is much higher than rhinovirus but lower than for influenza virus and similar to coxsackievirus when administered nasally.

Table 1 shows human studies in healthy volunteers on other relevant respiratory viruses.

a) Coronavirus

The human ID₅₀ for seasonal coronavirus subtype 229E that causes mild common cold in humans was reported to be 13 TCID₅₀ (6).

b) Influenza

The infective dose for H1N1 strain of influenza virus by nasal drop was 10³ TCID₅₀ (Table 1, B) (7). For the H2N2 strain by aerosol administration that TCID₅₀ was 0.6-3.0 TCID₅₀ (8), higher than by intranasal drop (127–320 TCID₅₀) (9). For the H3N2 strain by nasal drop was 1×10⁷ TCID₅₀ (10).

c) Rhinovirus

The TCID₅₀ of rhinovirus when administered by aerosols at 0.68 TCID₅₀ was about 20 times greater than by nasal drops (0.032 TCID₅₀) (11).

d) Adenovirus

For Adenovirus type 4 the TCID₅₀ was 35 TCID₅₀ by intranasal route and 0.5 TCID₅₀ by aerosol (12). In this study 6.6 particles by aerosol (corresponding to 462 particles by nasal drop) were required to initiate infection in 50% of the population. Furthermore, a high dose of virus by nasal drops was found to cause infection in the lower intestinal tract (12).

e) Coxsackievirus

TCID₅₀ of coxsackievirus A21 strain was 6 TCID₅₀ when administered by intranasal droplet compared with 28-34 TCID₅₀ by aerosol (11).

f) Respiratory syncytial virus (RSV)

Attenuated vaccine strain of RSV, TS-1, at a dose of 30-40 TCID₅₀ infected infants. This infectious dose of RSV is assumed to be lower than with the wild strain because of its lesser virulence through multiple passages in tissue culture (13). Type-39 had a TCID₅₀ of 100 (14).

3.3. Animal Studies

3.3.1 SARS-CoV-2

Table 2 summarizes experimental animal studies on SARS-CoV-2.

a) Ferret

Intranasal inoculation of $10^{5.5}$ TCID₅₀ (221,359 PFU) of SARS-CoV-2 virus presented raised body temperature and decreased activity in ferrets (15). One out of six ferrets that were infected by intranasal route at a dose of 500 PFU showed signs of upper respiratory tract viral replication. Meanwhile, all ferrets presented with pulmonary histopathological features and viral RNA replication at higher doses (50,000-5,000,000 PFU) (16, 17).

b) Mice

An study on hACE2 transgenic mice after intranasal inoculation at a dose of 10^5 TCID₅₀ (70,000 PFU) of SARS-CoV-2 showed weight loss and viral replication in the lungs (18). Another study on both young and aged hACE2 mice after infection at a dose of 400,000 PFU ($\approx 5.71 \times 10^5$ TCID₅₀) by intranasal route showed mild weight loss (10%) and more severe histopathological features of interstitial pneumonia in aged mice (19). Mice infected by the intragastric route at a dose of 4,000,000 PFU ($\approx 5.71 \times 10^6$ TCID₅₀) showed pulmonary infection in one of three mice (19). Transgenic mice after aerosol inoculation of SARS-CoV-2 isolates at a dose of 630 PFU showed viral RNA, interstitial pneumonia, and pulmonary infiltration after at least 25 min exposure to the virus (20). After intranasal infection with 21000 PFU of SARS-CoV-2, three out of six hACE2 mice died at 6 days post infection (21). Similarly 40% mortality in BALB/c mice was observed after intranasal infection with SARS-CoV-2 at a dose of 100,000 PFU (22). BALB/c mice showed viral replication and interstitial pneumonia at a dose of 16,000 PFU by the intranasal route (23).

c) Cynomolgus macaques

After aerosol inoculation at a dose of 48,600 PFU macaques presented modest clinical signs, viral RNA, and pulmonary pathological features (24). After inoculation at a dose of 700,000 PFU (10^6 TCID₅₀) of SARS-CoV-2 intranasally and intrathecally, cynomolgus macaques presented no clinical signs, however, histopathological changes indicating diffuse alveolar damage and viral replication were observed (25).

d) Rhesus macaques

Rhesus macaques infected with SARS-CoV-2 at a dose of 700,000 PFU (10^6 TCID₅₀) via ocular conjunctivae presented mild pneumonia and higher viral RNA than those infected intrathecally, whereas no viral RNA was detected after exposure by the intragastric route (26). After inoculation at a dose of 2,600,000 TCID₅₀ (1,820,000 PFU) of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes, macaques showed various range of clinical signs including weight loss, piloerection, decreased appetite, pallor and dehydration (27). Exposure to higher doses and correlation with signs of infection such as decrease in appetite and response to stimuli as well as slight neutropenia and lymphopenia was observed in a group of rhesus macaques that were infected at a dose of 1,100,000 PFU ($\approx 1.57 \times 10^6$ TCID₅₀). Two groups of rhesus macaques that were infected by intranasal and intrathecal route at a dose of 110,000 PFU ($\approx 1.57 \times 10^5$ TCID₅₀) and 110,000 PFU ($\approx 1.57 \times 10^4$ TCID₅₀) presented mild clinical disease. Histopathological features of pneumonia were observed at a dose of 110,000 PFU (28). Rhesus macaques exposed by aerosol route at a dose of 28700 PFU showed mild clinical signs of pulmonary infection (24).

e) African green monkey

All three African green monkeys exposed to 36000 PFU by the aerosol route showed clinical signs of pulmonary disease (24). African green monkeys inoculated by combined intranasal and intrathecal routes at a dose of 500,000 PFU ($\approx 7.14 \times 10^5$ TCID₅₀) showed histopathological features of pulmonary lesions and no overt clinical signs of disease (29). At a dose of 3,000,000 PFU ($\approx 4.28 \times 10^6$ TCID₅₀) they showed efficient viral replication and respiratory signs of infection (30). Two African green monkeys exposed at a dose of 2000 PFU by the aerosol route and 3,610,000 PFU by combined route of intranasal, thecal, ocular and oral showed signs of acute respiratory distress syndrome (ARDS), increased level of interleukin 6 (IL6) and cytokine storm (31).

f) Hamsters

In two groups of juvenile and adult hamsters infected by intranasal and ocular routes with SARS-CoV-2 at a higher and lower dose of $10^{5.6}$ PFU ($\approx 5.68 \times 10^5$ TCID₅₀) and 1000 PFU ($\approx 1.42 \times 10^3$ TCID₅₀), respectively, higher dose infected hamsters presented more severe lung complications, earlier weight loss, and earlier pneumomediastinum than the lower dose group (32). Hamsters that

were intranasally inoculated at a dose of 56000 PFU showed weight loss and viral shedding (33). After intranasal infection at a dose of 100,000 PFU hamsters showed both clinical presentation and viral RNA (34). Immunosuppressed hamsters after intranasal inoculation at doses of 100, and 1000 PFU showed extreme weight loss whereas death was observed in those exposed to 10,000 PFU (35).

g) Bats and other animals

Intranasal inoculation of 10^5 TCID₅₀ (70,000 PFU) of SARS-CoV-2 isolates into fruit bats, pigs, chickens, cats, dogs (data not tabulated for the latter four species) showed no clinical signs and viral RNA replication in except slight viral RNA and shedding in cats and bats (36, 37).

3.3.2 Other Coronaviruses

We examined findings on other coronaviruses, including Seasonal CoV, SARS-CoV-1 and MERS-CoV for relevant insights. Two group of BALB/c mice and C57BL/6 mice after infection with HCoV-OC43 at a dose of 10^5 TCID₅₀ (70,000 PFU) by intraperitoneal and intracerebral route showed 100% lethality at 8 days (38). However, at a dose of 10^4 - 10^5 TCID₅₀ (7000-70,000 PFU) they presented no clinical signs and viral RNA by intraoral route and mild signs of infection by intranasal route at 21 days postnatal (38). In another study twelve days old BALB/c mice exposed by the intracerebral route at a dose of 100 TCID₅₀ (70 PFU) of wild type HCoV-OC43 showed 100% lethality 4 days later (39). Estimated infectivity of SARS-CoV-1 was comparable to other coronaviruses including HCoV-229E a causative agent for a mild cold in humans. ID₁₀ and ID₅₀ of SARS-CoV-1 were reported as 43 and 280 PFU (400 TCID₅₀) in an experimental study (6). A study on transgenic mice reported the ID₅₀ of MERS-CoV as < 1 TCID₅₀ and LD₅₀ as 10 TCID₅₀ (40). Transgenic mice that were infected with MERS by the intranasal route presented signs of infection at a dose between 100 and 500,000 PFU (≈ 142 and $\approx 7.14 \times 10^5$ TCID₅₀) (41, 42).

3.4. Transmission route, exposure rate, and correlation with outcome

SARS-CoV-2 transmission is thought to be mainly through respiratory droplets and fomites rather than through aerosols carried over long distances (43). There are questions about whether the size of the infectious dose of COVID-19 and its route of transmission correlates with disease severity.

SARS-CoV-2 was not thought to be transmitted long distances by an aerosol in 75,465 COVID-19 patients in China (44). A study on aerosol distribution of SARS-CoV-2 in Wuhan hospital

reported the maximum distance of transmission as 4 meters in hospital wards. Reflecting this, an increased risk of positivity at sampling site and objects observed in patients' treatment areas (40.6%) than office areas of physicians (12.5%) (45).

SARS-CoV-1 is thought to be increased by 20.4-fold when people have at least exposure for >30 minutes and distance of <1m with infected patients (46). However, a safer physical distance to avoid transmission of SARS-CoV-2 is 1m as recommended as WHO and approximately as 2 m by CDC (47, 48). Small droplets can, nonetheless, be found at a distance of 7-8 meter away (49). The rate of COVID-19 transmission was increased by an estimated 18.7-fold in an enclosed area compared with the outdoor environment (50). Transmission of SARS-CoV-2 via contaminated surfaces or aerosolization was observed in cluster analysis of COVID-19 patients (51).

During the SARS-CoV-1 outbreak in 2003 the higher risk of infection was correlated with the amount and setting of exposure (46). in the Amoy-Garden housing complex in Hong-Kong, the lower concentrations of the virus explained the lower risk of infection in the upper floors (52). It was estimated that the apartment's residents were exposed to 16-160 PFU (\approx 22.8-228 TCID₅₀) per person depending on the floor (6).

Given the absence of direct information about SARS-CoV-2, findings from other respiratory viruses and in animals may provide clues. The potential of airborne, aerosol transmission of SARS-CoV-2 was observed in ferrets and cats (15, 53). Aerosol inoculation with the H3N2 strain of sub-lethal influenza virus in laboratory mice, presented exacerbated mortality and morbidity, pulmonary infiltration, and inflammation, as well as 6-fold higher levels of IL-6 expression in the lungs compared to intranasally inoculated mice (54). Consistently, African green monkeys infected by the aerosol route of SARS-CoV2 (table 2) presented with ARDS, increased level of IL6, and cytokine storms (31).

Increased exposure to the influenza virus, presumably reflecting increased infective dose, was correlated with disease progression (55). In addition to studies of SARS-CoV-2 infected ferrets, rhesus macaques, and hamsters (16, 28, 32, 35) studies on laboratory adapted mice infected with HCoV-OC43, SARS-CoV-1 and MERS reported increased morbidity and lethality with increasing dose at exposure (6, 41, 42).

3.5. SARS-CoV-2, viral load, and outcome

COVID-19 has lower morbidity and mortality, but greater infectivity, compared with SARS and MERS (56). The serial interval, the duration of the symptoms between the onset of symptoms in an index case and the secondary case, of COVID-19 together with viral shedding results suggest much transmission occurs early, even before onset of symptoms (57, 58). This interval is about 3-days for influenza virus (59), 4 days for COVID-19 (57), 8.4 days for SARS-CoV-1 (60) and 14.6 days for MERS-CoV (61). This means that infected people with SARS-CoV-2 and influenza can spread the virus faster than SARS-CoV-1 and MERS-CoV. Most COVID-19 studies show the highest viral load before or at and shortly after the onset of symptoms (58, 62-64) which may account for the rapid spreading of disease (65, 66). The high viral load in throat swabs at or just before onset of symptoms suggests that 44% of transmission can occur in the asymptomatic stages (63).

COVID-19 and influenza share a similar pattern of viral shedding (25, 58). There is correlation between higher viral load and the severity of COVID-19 (67, 68). Patients with severe symptoms of COVID-19 in one study presented 60 times higher viral load and prolonged viral shedding than patients with mild symptoms (69). In another study higher viral load was not correlated with outcomes including ICU admission, mortality, and oxygen requirement in hospitalized patients (70). In a study on 4172 patients, higher viral loads were observed in the first phase of the outbreak and the first phase of disease. The same study reported lower viral loads in ICU patients than patients in other wards (71).

A similar viral load was observed among different age groups in one study (71) while another study found a higher viral load in children aged <5 years than adults (72). The viral loads in asymptomatic patients were similar to those in patients with mild to moderate COVID-19 (58). Prolonged viral shedding, initial high viral load and increased risk of transmission in the early stage of disease was also observed in patients with seasonal coronavirus (OC43 and 229E) (73). Patients with single seasonal coronavirus had a higher viral load than patients with co-infection (74). Children with high viral loads of seasonal coronavirus were found to have an increased risk of symptomatic infection (73).

Studies on hamsters and African green monkeys reported no correlation between viral load and initial exposure dose of SARS-CoV-2 (31, 32) and SARS-CoV-1 (32, 75). In contrast viral load

and inoculating dose were associated in laboratory mice that were infected with SARS-CoV-1(76) respiratory syncytial virus (RSV) (77), and influenza virus (78).

During the SARS-CoV-1 outbreak at Amoy Gardens complex higher viral loads were detected in residents living in units adjacent to the index case indicating a link with exposure dose (79). Inter-study and inter-species variability highlight that correlation of viral load and dose at exposure is not unequivocal.

4. Discussion

Effective prevention and control strategies in the pandemic of COVID-19 require understanding of infective dose, transmission, and coinfection. We found limited evidence on these points requiring us to examine the data for other relevant viruses and to combine observations on animals and humans. In humans (table 1) the infective dose varies greatly by virus and route of administration. However, for coronavirus and influenza, mostly hundreds or even more virus particles are required to cause an infection. Similarly, in animals (table 2) the infective dose varies greatly by species and by route of administration. The infective dose is generally large, with hundreds and even millions of virus particles being required to induce disease. We estimate that the infective dose for COVID-19 is probably lower than for influenza (1000 TCID₅₀) as it is more contagious with a slightly higher R₀. The only human study on a coronavirus we found was on HCoV-229E with the TCID₅₀ comparison was 13 (6). The infective dose in humans for COVID-19 was estimated as $n \times 100$ particles based on computational analysis of nasopharynx in transmission and inhalation of droplets (80). In animals the minimum dose of SARS-CoV-2 that infected immunocompromised hamsters were also 100 particles (35), whereas healthy ferrets and transgenic mice were infected at slightly higher dose of 500 particle by nasal (16) and 630 particles by aerosol route (20). Possibly the higher value of 100 particle can be used as a potential surrogate for estimating the minimum infective dose of COVID-19 in humans. The data summarized here and in table 2 shows that the true measurement of infectious dose in animals and extrapolation to human is not possible. First, none of the animal studies reported the same clinical presentations and pathology after infection with SARS-CoV-2 as in humans. Second, different endpoint used for the measurement of infection, meanwhile susceptibility of animals can largely vary dependent on various species, ACE2 expression, age, and comorbidities. Third, the route of inoculation can

largely affect the response of animals to infection. All the animals infected by aerosol and other routes of exposure presented signs of infection whereas animals exposed by the intragastric route mostly remained asymptomatic (intranasal route being intermediate). In animals, the infective dose is generally lower with aerosol transmission than other routes. The infective dose in human could be lower than currently believed if transmission by aerosol is important. Moreover, aerosol transmission can allow the virus to penetrate into the lower respiratory tract of humans and cause severe symptoms (4).

The route of infection can impact on the induction of innate and adaptive immune responses (54). Little is known about the host immune response following different routes of infection with SARS-CoV-2. Higher viral load is not necessarily correlated with more severe symptoms, with some studies finding higher viral load in mildly symptomatic or asymptomatic stages of disease (65, 70, 71). This suggests a decline in viral load as the disease progresses (70, 71).

COVID-19 shares important features with influenza in serial interval of disease, clinical presentation, transmission route, viral load, infective dose, viral shedding, and correlation with outcome. Studies on influenza virus suggest a correlation between increasing body mass index (BMI) and increased aerosol shedding through increased frequency of small airway closure and reopening (81). High BMI is associated with critical illness and severity of symptoms in patients with COVID-19 and influenza (82, 83).

Exhaled breath of symptomatic patients with influenza can transmit an estimated 33 particles per minute in aerosol (81). Twenty minutes of exposure would be required for the exposure to the median infective dose of H1N1 subtype. Similarly, almost 25 particle per minute (630 particles in 25 min) in aerosol were required to cause COVID-19 infection in hACE2 mice (20). Exposure for a similar period to SARS-CoV-2 exhaled in normal breathing of infected patients could lead to the inhaling of our estimated hundreds of SARS-CoV-19 particles by aerosol, thus complementing infection by fomites and droplets. However, further studies are warranted to examine infective dose by the aerosol route and its correlation with COVID-19 severity and immune response both in animals through experiments and humans through observation.

5. Conclusion

SARS-CoV-2 has distinct features as well as commonalities compared with other similar respiratory pathogens justifying further experimental and observational studies concentrating on transmission, exposure, the infective dose, viral load, virus shedding, and the synergistic effect of viral dose and route of exposure and co-infection of SARS-CoV-2 with one or more respiratory pathogens. This review has merely laid the foundation in the study of this topic.

Table 1: Infective dose of relevant respiratory viruses in humans

Virus	Strain	Dose		Route of administration	References
		TCID ₅₀	PFU		
^a Coronavirus	HCoV-229E	13	9	NR	Watanabe et al. (6)
^b Influenza	H1N1	1.0×10 ³	700	Intranasal	Hayden et al. (7)
	H2N2	0.6-3	0.42-2.1	Aerosol	Alford et al. (8)
	H3N2	1.0×10 ⁷	7,000,000	Intranasal	Treanor et al. (10)
^c Rhinovirus	RV15	0.032	0.0224	Intranasal	Couch et al. (11)
^d Adenovirus	Type 4	0.5	0.35	Aerosol	Couch et al. (12)
^e Coxsackievirus	A21-48654	6	4.2	Intranasal	Couch et al. (11)
^f RSV	Ts-1	30-40 (33% infected)	21-28	Intranasal	Parrott et al. (13)
	Type 39	100	70	Aerosol	Bischoff et al. (14)

TCID₅₀, %50 Tissue Infective Culture Dose; PFU, plaque-forming units; tgMice, Transgenic Mice; RSV, Respiratory Syncytial Virus; MERS, Middle East Respiratory Syndrome; NR, not reported.

Table 2: Experimental studies on the infective dose of coronaviruses in various mammals

Virus	Host	Dose (PFU)	Route of inoculation	Numbers and/or %, signs of infection	References
SARS-CoV-2	^a Ferret	221,359	IN	6/6	Kim et al. (15)
		500	IN	16.7,1/6	Ryan et al. (16)
		50000		6/6	
		5,000,000		6/6	
		420,000	IN	4/4	Richard et al. (17)
SARS-CoV-2	^b hACE2 mice	70,000	IN	36.8,7/19	Bao et al. (18)
		400,000	IN	3/3	Sun et al. (19)
		4,000,000	IG	1/3	
		630	Aerosol	2/2	Bao et al. (20)
		21000	IN	50% Lethal	Jiang et al. (21)
		100,000	IN	40% Lethal	Dinnon et al. (22)
		16,000	IN	3/3	Gu at al. (23)
HCoV-OC43	BALB/c & C57B6 mice	70,000	IP/IC	100% Lethal	Jacomy et al. (38)
	BALB/c mice	70	IC	100% Lethal	Shen et al. (39)
SARS-CoV-1	tgMice	280	IN	NR	Watanabe et al. (6)
MERS-CoV	tgMice	0.7	IN	NR	Tao et al. (40)
		7		50% Lethal	
SARS-CoV-2	^c Cynomolgus macaques	48,600	Aerosol	4/4	Johnston et al. (24)
		700,000	IN/IT	4/4	Rockx et al. (25)

Table 2: Continued

Virus	Host	Dose (PFU)	Route of inoculation	Numbers and/or %, signs of infection	References		
SARS-CoV-2	^d Rhesus macaques	700,000	IO	2/2	Deng et al. (26)		
			IT	1/1			
			IG	0/2			
				1,820,000	IN/IT/IO/Oral	8/8	Munster et al. (27)
				11,000	IN/IT	3/3	Chandrashekar et al. (28)
				110,000		3/3	
				1,100,000		3/3	
		28700	Aerosol	4/4	Johanston et al. (24)		
SARS-CoV-2	^e African green monkeys	38000	Aerosol	3/3	Johanston et al. (24)		
		500,000	IN/IT	6/6	Woolsey et al. (29)		
		3,000,000	IN	6/6	Cross et al. (30)		
		2000	Aerosol	2/2	Blair et al. (31)		
		3,610,000	IO/IT/IN/Oral	2/2			
SARS-CoV-2	^f Syrian hamster	398,107	IN/IO	4/4	Imai et al. (32)		
		1000		4/4			
		56000	IN	3/3	Sia et al. (33)		
		100,000	IN	75,24/36	Osterrieder et al. (34)		
		Immunocompromised Syrian hamster	100	IN	10/10	Brocato et al. (35)	
			1000				
			10,000		40%Lethal		
		^g Bats	70,000	IN	78,7/9	Schlottau et al. (36)	

TCID₅₀, %50 Tissue Infective Culture Dose; PFU, plaque-forming units; tgMice, Transgenic Mice; hACE2, human angiotensin converting enzyme 2, BALB/c; begg albino laboratory-bred mouse, IN; intranasal, IG; intragastric, IO; intraocular, IT; intrathecal, IC; intracerebral, IP; intraperitoneal, NR; not reported

References

1. Warnes SL, Little ZR, Keevil CW. Human coronavirus 229E remains infectious on common touch surface materials. *MBio*. 2015;6(6):e01697-15.
2. Ward RL, Akin EW, D'Alessio DJ. Minimum infective dose of animal viruses. *Critical Reviews in Environmental Control*. 1984;14(4):297-310.
3. Carter J, Saunders V, Saunders VA. *Virology: principles and applications*: John Wiley & Sons; 2007.
4. Yezli S, Otter JA. Minimum infective dose of the major human respiratory and enteric viruses transmitted through food and the environment. *Food and Environmental Virology*. 2011;3(1):1-30.
5. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States. *Emerging Infectious Diseases*. 2020;26(6).
6. Watanabe T, Bartrand TA, Weir MH, Omura T, Haas CN. Development of a dose-response model for SARS coronavirus. *Risk Analysis: An International Journal*. 2010;30(7):1129-38.
7. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. *Jama*. 1996;275(4):295-9.
8. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol inhalation. *Proceedings of the Society for Experimental Biology and Medicine*. 1966;122(3):800-4.
9. Tellier R. Review of aerosol transmission of influenza A virus. *Emerging infectious diseases*. 2006;12(11):1657.
10. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. *Vaccine*. 1999;18(9-10):899-906.
11. Couch RB, Cate TR, Douglas Jr RG, Gerone PJ, Knight V. Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. *Bacteriological reviews*. 1966;30(3):517.
12. Couch R, Knight V, Douglas Jr R, Black S, Hamory B. The minimal infectious dose of adenovirus type 4; the case for natural transmission by viral aerosol. *Transactions of the American Clinical and Climatological Association*. 1969;80:205.
13. Parrott R, Kim H, Brandt C, Chanock R. Potential of attenuated respiratory syncytial virus vaccine for infants and children. *Developments in biological standardization*. 1975;28:389-99.
14. Bischoff WE. Transmission route of rhinovirus type 39 in a monodispersed airborne aerosol. *Infection Control & Hospital Epidemiology*. 2010;31(8):857-9.
15. Kim Y-I, Kim S-G, Kim S-M, Kim E-H, Park S-J, Yu K-M, et al. Infection and rapid transmission of sars-cov-2 in ferrets. *Cell host & microbe*. 2020. <https://doi.org/10.1016/j.chom.2020.03.023>.
16. Ryan KA, Bewley KR, Fotheringham SA, Brown P, Hall Y, Marriott AC, et al. Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.05.29.123810>.
17. Richard M, Kok A, de Meulder D, Bestebroer TM, Lamers MM, Okba NM, et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.04.16.044503>.
18. Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature*. 2020.
19. Sun S-H, Chen Q, Gu H-J, Yang G, Wang Y-X, Huang X-Y, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. *Cell Host & Microbe*. 2020. doi: [10.1016/j.chom.2020.05.020](https://doi.org/10.1016/j.chom.2020.05.020).
20. Bao L, Gao H, Deng W, Lv Q, Yu H, Liu M, et al. Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice. *The Journal of infectious diseases*. 2020;222(4):551-5.
21. Jiang R-D, Liu M-Q, Chen Y, Shan C, Zhou Y-W, Shen X-R, et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. *Cell*. 2020;182(1):50-8. e8.
22. Dinno KH, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, et al. A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures. *bioRxiv*. 2020.
23. Gu H, Chen Q, Yang G, He L, Fan H, Deng Y-Q, et al. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science*. 2020:eabc4730.

24. Johnston SC, Jay A, Raymond JL, Rossi F, Zeng X, Scruggs J, et al. Development of a Coronavirus Disease 2019 Nonhuman Primate Model Using Airborne Exposure. *bioRxiv*. 2020. doi: [10.1101/2020.06.26.174128](https://doi.org/10.1101/2020.06.26.174128).
25. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Munnink BBO, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science*. 2020; 29;368(6494):1012-1015.
26. Deng W, Bao, L., Gao, H. et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. *Nat Commun* 11, 4400 (2020).
27. Munster VJ, Feldmann F, Williamson BN, Van Doremalen N, Pérez-Pérez L, Schulz J, et al. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *BioRxiv*. 2020. <https://doi.org/10.1101/2020.03.21.001628>.
28. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science*. 2020; 14;369(6505):812-817.
29. Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, et al. Establishment of an African green monkey model for COVID-19. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.05.17.100289>.
30. Cross RW, Agans KN, Prasad AN, Borisevich V, Woolsey C, Deer DJ, et al. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. *Virology Journal*. 2020;17(1):1-12.
31. Blair RV, Vaccari M, Doyle-Meyers LA, Roy CJ, Russell-Lodrigue K, Fahlberg M, et al. ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.06.18.157933>.
32. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proceedings of the National Academy of Sciences*. 2020; 117 (28) 16587-16595.
33. Sia SF, Yan L-M, Chin AW, Fung K, Choy K-T, Wong AY, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature*. 2020;583(7818):834-8.
34. Osterrieder N, Bertzbach LD, Dietert K, Abdelgawad A, Vladimirova D, Kunec D, et al. Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. *bioRxiv*. 2020. <https://doi.org/10.1101/2020.06.10.144188>.
35. Brocato R, Principe L, Kimi R, Zeng X, Williams J, Liu Y, et al. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters. 2020. <https://doi.org/10.1101/2020.06.19.161612>.
36. Schlottau K, Rissmann M, Graaf A, Schön J, Sehl J, Wylezich C, et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *The Lancet Microbe*. 2020 ; 1: e218–25.
37. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science*. 2020;368(6494):1016-20.
38. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected by human coronavirus OC43. *Virology*. 2003;315(1):20-33.
39. Shen L, Yang Y, Ye F, Liu G, Desforges M, Talbot PJ, et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. *Antimicrobial agents and chemotherapy*. 2016;60(9):5492-503.
40. Tao X, Garron T, Agrawal AS, Algaissi A, Peng B-H, Wakamiya M, et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. *Journal of virology*. 2016;90(1):57-67.
41. Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology*. 2016;2(2):1-11.
42. Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell AK, Reznikov LR, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. *The Journal of infectious diseases*. 2016;213(5):712-22.
43. World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations [Available from: <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>] [Accessed 10 Jun 2020].
44. Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. *Jama*. 2020;323(16):1610-2.
45. Guo Z-D, Wang Z-Y, Zhang S-F, Li X, Li L, Li C, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. *Emerg Infect Dis*. 2020;26(7).

46. Rea E, Lafleche J, Stalker S, Guarda B, Shapiro H, Johnson I, et al. Duration and distance of exposure are important predictors of transmission among community contacts of Ontario SARS cases. *Epidemiology & Infection*. 2007;135(6):914-21.
47. World Health Organization. Coronavirus disease (COVID-19) advice for the public [Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public>] [Accessed 10 Jun 2020].
48. Center for Disease Control and Prevention. Social Distancing Keep a Safe Distance to Slow the Spread [Available from: <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html>] [Accessed 25 Jun 2020].
49. Bourouiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. *JAMA*. 2020;323(18):1837-8.
50. Nishiura H, Oshitani H, Kobayashi T, Saito T, Sunagawa T, Matsui T, et al. Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). *medRxiv*. 2020. <https://doi.org/10.1101/2020.02.28.20029272>.
51. Cai J, Sun W, Huang J, Gamber M, Wu J, He G. Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020. *Emerg Infect Dis*. 2020;26(6).
52. Yu IT, Li Y, Wong TW, Tam W, Chan AT, Lee JH, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. *New England Journal of Medicine*. 2004;350(17):1731-9.
53. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science*. 2020:eabb7015.
54. Smith JH, Nagy T, Barber J, Brooks P, Tompkins SM, Tripp RA. Aerosol inoculation with a sub-lethal influenza virus leads to exacerbated morbidity and pulmonary disease pathogenesis. *Viral immunology*. 2011;24(2):131-42.
55. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi K-W, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. *The Journal of infectious diseases*. 2009;200(4):492-500.
56. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *International journal of epidemiology*. 2020. doi: 10.1093/ije/dyaa033.
57. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. *International journal of infectious diseases*. 2020. doi: 10.1016/j.ijid.2020.02.060.
58. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine*. 2020;382(12):1177-9.
59. Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 80. 2020.
60. Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission dynamics and control of severe acute respiratory syndrome. *Science*. 2003;300(5627):1966-70.
61. Park SH, Kim Y-S, Jung Y, Cho N-H, Jeong HW, Heo JY, et al. Outbreaks of Middle East respiratory syndrome in two hospitals initiated by a single patient in Daejeon, South Korea. *Infection & chemotherapy*. 2016;48(2):99-107.
62. Han MS, Seong M-W, Kim N, Shin S, Cho S, Park H, et al. Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul. *Emerging infectious diseases*. 2020;26(10).
63. He X, Lau EH, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature medicine*. 2020:1-4.
64. Huang J, Mao T, Li S, Wu L, Xu X, Li H, et al. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv*. 2020. <https://doi.org/10.1101/2020.04.22.20071258>.
65. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*. 2020; 20: 565–74.
66. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi J-P, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. *Journal of Korean medical science*. 2020;35(13).
67. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *bmj*. 2020;369.
68. Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. *Critical Care*. 2020;24:1-4.

69. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious Diseases*. 2020; 20(6):656-657.
70. Argyropoulos KV, Serrano A, Hu J, Black M, Feng X, Shen G, et al. ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS. *The American journal of pathology*. 2020; 190(9): 1881–1887.
71. Jacot D, Greub G, Jatou K, Opota O. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. *medRxiv*. 2020. doi: 10.1101/2020.07.15.20154518.
72. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). *JAMA Pediatrics*. 2020; 174(9):902-903.
73. Ogimi C, Kim YJ, Martin ET, Huh HJ, Chiu C-H, Englund JA. What's New With the Old Coronaviruses? *Journal of the Pediatric Infectious Diseases Society*. 2020;9(2):210-7.
74. Fielding BC. Human coronavirus NL63: a clinically important virus? *Future microbiology*. 2011;6(2):153-9.
75. Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. *Journal of virology*. 2005;79(1):503-11.
76. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *Journal of virology*. 2004;78(7):3572-7.
77. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. *Journal of medical virology*. 1988;26(2):153-62.
78. Taylor R. Experimental infection with influenza A virus in mice: the increase in intrapulmonary virus after inoculation and the influence of various factors thereon. *The Journal of experimental medicine*. 1941;73(1):43-55.
79. Chu C-M, Cheng VC, Hung IF, Chan K-S, Tang BS, Tsang TH, et al. Viral load distribution in SARS outbreak. *Emerging infectious diseases*. 2005;11(12):1882.
80. Basu S. Close-range exposure to a COVID-19 carrier: transmission trends in the respiratory tract and estimation of infectious dose. *medRxiv*. 2020. doi: 10.1101/2020.07.27.20162362.
81. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proceedings of the National Academy of Sciences*. 2018;115(5):1081-6.
82. Caussy C, Pattou F, Wallet F, Simon C, Chalopin S, Telliame C, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. *The Lancet Diabetes & Endocrinology*. 2020. doi: 10.1016/S2213-8587(20)30160-1.
83. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. *Clinical Infectious Diseases*. 2011;53(5):413-21.